Table 3.
Characteristics of men with localized prostate cancer in high- and low-use primary androgen-deprivation therapy health service areas
| Low risk | High risk | All localized cancer | ||||
|---|---|---|---|---|---|---|
| Characteristic | High use, n = 8060 |
Low use, n = 7508 |
High use, n = 2522 |
Low use, n = 2811 |
High use, n = 12 087 |
Low use, n = 10 014 |
| PADT therapy within 12 mo, no. (%) |
3174 (39.4) | 1710 (22.8) | 1818 (72.1) | 1590 (56.6) | 5687 (47.1) | 3146 (31.4) |
| Duration of PADT use, mo, mean (SD) |
44 (39) | 36 (34) | 40 (33) | 35 (30) | 43 (37) | 35 (33) |
| Age at diagnosis, yr, median (IQR) |
78 (73–82) | 77 (73–81) | 80 (76–84) | 79 (75–84) | 78 (74–82) | 78 (73–82) |
| Zip code–level income, US$ , median (IQR) |
46 199 (36 183–62 749) |
45 057 (35 792–58 482) |
42 235 (35 728–58 814) |
46 177 (33 359–55 994) |
45 361 (35 602–61 081) |
45 007 (35 792–57 636) |
| Charlson score, mean (SD) | 0.43 (0.86) | 0.35 (0.79) | 0.43 (0.85) | 0.51 (0.94) | 0.44 (0.86) | 0.37 (0.80) |
| Clinical stage T1, no. (%) | 3749 (46.5) | 3362 (44.8) | 832 (33.0) | 841 (29.9) | 5226 (43.2) | 4098 (40.9) |
| PSA, mean (SD)a | 11.2 (14.5) | 9.0 (9.5) | 22.4 (24.7) | 19.8 (22.6) | 15.0 (18.9) | 14.8 (18.8) |
| Gleason score 2–6, no. (%)a | 1071 (13.3) | 1119 (14.9) | 0 | 0 | 1186 (9.8) | 1124 (11.2) |
| Gleason score 7, no. (%)a | 0 | 0 | 486 (19.3) | 665 (23.7) | 659 (5.5) | 542 (5.4) |
| Gleason score 8–10, no. (%)a | 0 | 0 | 278 (11.0) | 380 (13.5) | 349 (2.9) | 316 (3.2) |
PADT = primary androgen-deprivation therapy; SD = standard deviation; IQR = interquartile range; PSA = prostate-specific antigen.
a
Limited to patients diagnosed in 2004 or thereafter.